183 related articles for article (PubMed ID: 36333718)
1. Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics-a prospective multicenter cohort study.
van Opijnen MP; Broekman MLD; de Vos FYF; Cuppen E; van der Hoeven JJM; van Linde ME; Compter A; Beerepoot LV; van den Bent MJ; Vos MJ; Fiebrich HB; Koekkoek JAF; Hoeben A; Kho KH; Driessen CML; Jeltema HR; Robe PAJT; Maas SLN
BMC Med Genomics; 2022 Nov; 15(1):233. PubMed ID: 36333718
[TBL] [Abstract][Full Text] [Related]
2. Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
Samsom KG; Bosch LJW; Schipper LJ; Roepman P; de Bruijn E; Hoes LR; Riethorst I; Schoenmaker L; van der Kolk LE; Retèl VP; Frederix GWJ; Buffart TE; van der Hoeven JJM; Voest EE; Cuppen E; Monkhorst K; Meijer GA
BMC Med Genomics; 2020 Nov; 13(1):169. PubMed ID: 33167975
[TBL] [Abstract][Full Text] [Related]
3. LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study.
Kong BY; Sim HW; Nowak AK; Yip S; Barnes EH; Day BW; Buckland ME; Verhaak R; Johns T; Robinson C; Thomas MA; Giardina T; Lwin Z; Scott AM; Parkinson J; Jeffree R; Lourenco RA; Hovey EJ; Cher LM; Kichendasse G; Khasraw M; Hall M; Tu E; Amanuel B; Koh ES; Gan HK
BMJ Open; 2021 Dec; 11(12):e054075. PubMed ID: 37185327
[TBL] [Abstract][Full Text] [Related]
4. ALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma.
Pepper NB; Eich HT; Müther M; Oertel M; Rehn S; Spille DC; Stummer W
Radiat Oncol; 2024 Jan; 19(1):11. PubMed ID: 38254201
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma: Overview of Disease and Treatment.
Davis ME
Clin J Oncol Nurs; 2016 Oct; 20(5 Suppl):S2-8. PubMed ID: 27668386
[TBL] [Abstract][Full Text] [Related]
6. Whole genome sequencing in (recurrent) glioblastoma: challenges related to informed consent procedures and data sharing.
Hasner MC; van Opijnen MP; de Vos FYF; Cuppen E; Broekman MLD
Acta Neurochir (Wien); 2024 Jun; 166(1):266. PubMed ID: 38874628
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
9. Molecularly targeted therapies for recurrent glioblastoma: current and future targets.
Lau D; Magill ST; Aghi MK
Neurosurg Focus; 2014 Dec; 37(6):E15. PubMed ID: 25434384
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors.
Schäfer N; Gielen GH; Rauschenbach L; Kebir S; Till A; Reinartz R; Simon M; Niehusmann P; Kleinschnitz C; Herrlinger U; Pietsch T; Scheffler B; Glas M
J Transl Med; 2019 Mar; 17(1):96. PubMed ID: 30894200
[TBL] [Abstract][Full Text] [Related]
12. Study protocol for a multicenter randomised controlled trial on the (cost)effectiveness of biopsy combined with same-session MR-guided LITT versus biopsy alone in patients with primary irresectable glioblastoma (EMITT trial).
Neutel CLG; Viozzi I; Overduin CG; Rijpma A; Grutters JPC; Hannink G; van Eijsden P; Robe PA; Rovers MM; Ter Laan M
BMC Cancer; 2023 Aug; 23(1):788. PubMed ID: 37612610
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape.
Mohme M; Maire CL; Schliffke S; Joosse SA; Alawi M; Matschke J; Schüller U; Dierlamm J; Martens T; Pantel K; Riethdorf S; Lamszus K; Westphal M
Acta Neuropathol Commun; 2020 Mar; 8(1):28. PubMed ID: 32151286
[TBL] [Abstract][Full Text] [Related]
14. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
Padovan M; Maccari M; Bosio A; De Toni C; Vizzaccaro S; Cestonaro I; Corrà M; Caccese M; Cerretti G; Zagonel V; Lombardi G
Eur J Cancer; 2023 Sep; 191():112959. PubMed ID: 37481865
[TBL] [Abstract][Full Text] [Related]
15. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Wick W; Dettmer S; Berberich A; Kessler T; Karapanagiotou-Schenkel I; Wick A; Winkler F; Pfaff E; Brors B; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Eisenmenger A; von Deimling A; Jones DTW; Pfister SM; Sahm F; Platten M
Neuro Oncol; 2019 Jan; 21(1):95-105. PubMed ID: 30277538
[TBL] [Abstract][Full Text] [Related]
16. Molecular Evolution of
Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
[TBL] [Abstract][Full Text] [Related]
17. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
[TBL] [Abstract][Full Text] [Related]
18. Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes.
Hundsberger T; Hottinger AF; Roelcke U; Roth P; Migliorini D; Dietrich PY; Conen K; Pesce G; Hermann E; Pica A; Gross MW; Brügge D; Plasswilm L; Weller M; Putora PM
J Neurooncol; 2016 Jan; 126(1):175-183. PubMed ID: 26459327
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic pathways and glioblastoma treatment.
Clarke J; Penas C; Pastori C; Komotar RJ; Bregy A; Shah AH; Wahlestedt C; Ayad NG
Epigenetics; 2013 Aug; 8(8):785-95. PubMed ID: 23807265
[TBL] [Abstract][Full Text] [Related]
20. Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial.
Lim J; Park Y; Ahn JW; Sim J; Kang SJ; Hwang S; Chun J; Choi H; Kim SH; Chun DH; Sung KS; Kwack K; Cho K
PLoS One; 2021; 16(3):e0247293. PubMed ID: 33690665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
